Global Trust Asset Management LLC Sells 950 Shares of Sanofi (NASDAQ:SNY)

Global Trust Asset Management LLC decreased its position in Sanofi (NASDAQ:SNY) by 34.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 1,821 shares of the company’s stock after selling 950 shares during the period. Global Trust Asset Management LLC’s holdings in Sanofi were worth $88,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Stablepoint Partners LLC boosted its holdings in shares of Sanofi by 0.8% during the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after acquiring an additional 189 shares during the period. PDS Planning Inc boosted its stake in Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after purchasing an additional 200 shares during the period. Eagle Ridge Investment Management grew its holdings in Sanofi by 3.8% in the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after buying an additional 203 shares in the last quarter. Financial Advocates Investment Management increased its position in Sanofi by 3.4% during the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after buying an additional 206 shares during the period. Finally, Angeles Investment Advisors LLC lifted its holdings in shares of Sanofi by 1.9% during the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after buying an additional 210 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $51.51 on Thursday. The company has a market cap of $130.72 billion, a price-to-earnings ratio of 26.28, a PEG ratio of 1.19 and a beta of 0.57. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock has a fifty day moving average price of $48.53 and a 200-day moving average price of $52.16.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the prior year, the business posted $2.55 earnings per share. Sanofi’s revenue was up 12.3% compared to the same quarter last year. As a group, equities analysts anticipate that Sanofi will post 3.82 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.